NEW YORK (GenomeWeb) – MdxHealth announced today that it has raised €12.3 milllion ($15.4 million) in a private placement. The firm sold 3.4 million shares at €3.60 per share to a group of institutional, qualified and professional investors.

"In combination with our existing cash position, these funds allow us to support and scale up MDxHealth's US-based managed care and related healthcare reimbursement efforts," Jan Groen, CEO of MDxHealth, said in a statement. "In addition, it will allow us to accelerate product development and finance general corporate purposes."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.